

previously immunized with human T cells which reacts with essentially all normal human peripheral T cells but not with normal human peripheral B cells, null cells, or macrophages.

Claim 26, line 1, after "preparing" insert -- complement-fixing --.

REMARKS

Reconsideration is respectfully requested.

All of the pending claims in the application (1-3, 15-18, and 22-26) have been rejected on a variety of grounds. Applicants respectfully submit, however, that these claims are allowable for the reasons presented below. Accordingly withdrawal of the rejection and transmission of a notice of allowance are respectfully requested.

Newly-presented Claims 27-30 are product claims wherein the monoclonal antibody is prepared by the method of Claims 23-26. Claim 31 is also a product claim, support for which will be found in the specification, particularly at page 5, line 32, through page 7, line 38. It is believed that these claims are also allowable.

A. Deposit of Hybridoma

Attached hereto as Exhibit A is a photocopy of a letter from the American Type Culture Collection evidencing the deposit of the subject hybridoma in a form which is believed to satisfy the requirements of MPEP Section 608.01(p) and In re Argoudelis. That is, the ATCC has agreed to irrevocably remove restrictions on the availability of the culture deposit on the granting of the patent and has agreed to maintain the deposit for a period of thirty years from the deposit date, which period will certainly exceed the term of a patent issuing from the subject application.